Tourmaline Bio Inc (NAS:TRML)
$ 13.45 -0.21 (-1.54%) Market Cap: 344.95 Mil Enterprise Value: 52.26 Mil PE Ratio: 0 PB Ratio: 0.97 GF Score: 22/100

Talaris Therapeutics Inc FREEDOM-1 Data Update Conference Call Transcript

Jun 30, 2022 / 12:00PM GMT
Operator

Good day. And thank you for standing by. Welcome to the Talaris FREEDOM-1 Data Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I will now like to hand the conference over to your speaker today, Mary Kay Fenton, Chief Financial Officer. Please go ahead.

Mary Kay Fenton
Talaris Therapeutics Inc. - Chief Financial Officer

Good morning. My name is Mary Kay Fenton, Talaris' Chief Financial Officer. I'm joined today by my colleagues, Scott Requadt, our Chief Executive Officer, and Nancy Krieger, our Chief Medical Officer.

Before we begin today's presentation I need to remind everyone that our presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including without limitation implied and expressed statements regarding Talaris' strategy and focus, and the progress and results of clinical development of Talaris' Clinical Candidate FCFCR001.

Any forward-looking statements we make

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot